We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · November 16, 2020

COSA 2020: Adjuvant Osimertinib Provides an Effective New Treatment Strategy for EGFR-Mutated NSCLC

Osimertinib is more effective than other EGFR TKIs.

PracticeUpdate Editorial Team

 

Further Reading